tiprankstipranks
Advertisement
Advertisement

CLDX Stock Latest News

CLDX Earnings this Week: How Will it Perform?
Pre-EarningsCLDX Earnings this Week: How Will it Perform?
3d ago
CLDX
Morning News Wrap-Up, 4/20/26: Today’s Biggest Stock Market Stories!
PremiumMarket News
Morning News Wrap-Up, 4/20/26: Today’s Biggest Stock Market Stories!
11d ago
AMD
DIA
A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX)
PremiumMarket News
A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX)
11d ago
CLDX
Celldex upgraded to Overweight from Underweight at Barclays
PremiumThe Fly
Celldex upgraded to Overweight from Underweight at Barclays
11d ago
CLDX
Celldex Announces Major Underwritten Public Equity Offering
PremiumCompany Announcements
Celldex Announces Major Underwritten Public Equity Offering
29d ago
8K
CLDX
Celldex 10.345M share Spot Secondary priced at $29.00
PremiumThe FlyCelldex 10.345M share Spot Secondary priced at $29.00
29d ago
CLDX
Closing Bell Movers: Globalstar spikes on acquisition report
Premium
The Fly
Closing Bell Movers: Globalstar spikes on acquisition report
30d ago
FC
AMZN
Celldex announces common stock offering, no amount given
Premium
The Fly
Celldex announces common stock offering, no amount given
30d ago
CLDX
Celldex data shows improvements across six DLQI Domains in barzolvolimab trials
PremiumThe Fly
Celldex data shows improvements across six DLQI Domains in barzolvolimab trials
1M ago
CLDX
Celldex upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe Fly
Celldex upgraded to Outperform from Peer Perform at Wolfe Research
1M ago
CLDX
Celldex price target raised to $34 from $30 at Goldman Sachs
PremiumThe Fly
Celldex price target raised to $34 from $30 at Goldman Sachs
2M ago
CLDX
Celldex: Barzolvolimab’s Durable Efficacy in Chronic Urticaria Underpins Buy Rating Ahead of Key Late-Stage Catalysts
PremiumRatings
Celldex: Barzolvolimab’s Durable Efficacy in Chronic Urticaria Underpins Buy Rating Ahead of Key Late-Stage Catalysts
2M ago
CLDX
Celldex presents new data from Phase 2 ColdU, SD Open Label Extension
PremiumThe FlyCelldex presents new data from Phase 2 ColdU, SD Open Label Extension
2M ago
CLDX
Celldex price target raised to $44 from $43 at Morgan Stanley
Premium
The Fly
Celldex price target raised to $44 from $43 at Morgan Stanley
2M ago
CLDX
Celldex price target raised to $68 from $58 at Stifel
Premium
The Fly
Celldex price target raised to $68 from $58 at Stifel
2M ago
CLDX
Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating
PremiumRatings
Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating
2M ago
CLDX
Maintaining Buy on Barzolvolimab: Accelerated Clinical Execution, Best-in-Class Potential, and 2026 Catalyst-Driven Upside
PremiumRatings
Maintaining Buy on Barzolvolimab: Accelerated Clinical Execution, Best-in-Class Potential, and 2026 Catalyst-Driven Upside
2M ago
CLDX
Celldex reports Q4 EPS ($1.22), consensus ($1.00)
PremiumThe Fly
Celldex reports Q4 EPS ($1.22), consensus ($1.00)
2M ago
CLDX
Celldex completes enrollment in Phase 3 studies of barzolvolimab
PremiumThe Fly
Celldex completes enrollment in Phase 3 studies of barzolvolimab
2M ago
CLDX
Celldex’s EvolvE Study Completion Sets Up Key Catalyst in Eosinophilic Esophagitis
PremiumCompany AnnouncementsCelldex’s EvolvE Study Completion Sets Up Key Catalyst in Eosinophilic Esophagitis
3M ago
CLDX
Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
Premium
Company Announcements
Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
3M ago
CLDX
Celldex Advances Barzolvolimab Into Phase 3 for Chronic Inducible Urticaria: What Investors Should Watch
Premium
Company Announcements
Celldex Advances Barzolvolimab Into Phase 3 for Chronic Inducible Urticaria: What Investors Should Watch
4M ago
CLDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >